Treatment of disorders associated with G protein-coupled receptor 35 (GPR35)
Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation.
1. A method of providing neuroprotection in case of stroke or ischemia to a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 are independently F, Cl, Br or I; and,
n is 0 or 1;
wherein said pharmaceutically acceptable salt comprises a cationic counterion which itself does not provide therapeutically useful neuroprotection in case of stroke or ischemia to said subject.
2. The method of claim 1 , wherein said compound of Formula (I) is 7,7′-dibromo-pamoic acid or a pharmaceutically acceptable salt thereof.
3. A method of providing neuroprotection in case of stroke or ischemia to a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of 1,1′-binaphtyl-2,2′-diol -3,3′-dicarboxylic acid, or a pharmaceutically acceptable salt thereof wherein said pharmaceutically acceptable salt comprises a cationic counterion which itself does not provide therapeutically useful neuroprotection in case of stroke or ischemia to said subject.